



“Eversense is the first CGM I’ve ever been able to stick with.”

## We know why many patients abandon traditional CGM. Eversense<sup>®</sup> CGM is tackling those barriers head-on.

### ► CHALLENGE:

One in four patients (27%) abandon CGM in the first year<sup>1</sup>, and up to 39%<sup>2</sup> do not achieve the minimum 70% wear time associated with clinical efficacy.<sup>3,4</sup> Though the reasons are well understood, traditional CGM systems do not address patient burden and discretion — the most common barriers to CGM adherence.

### ► OPPORTUNITY:

Incorporate features and functionality into a CGM system that overcome or even eliminate common factors that limit adherence.

### ► MEET TRE

A 24-year-old Type 1 patient who was diagnosed 12 years ago, Tre works in his family’s business where he has an erratic schedule. Tre was not able to maintain consistent CGM use because of repeated issues with self-insertion and sensors falling out, and he didn’t always trust the results.

Tre immediately liked the convenience of the Eversense CGM System, and its on-body alerts helped him stay on track at work, in the warehouse or in the truck. His anxiety about insertion site management disappeared and he found himself wearing his Eversense CGM over 80% of the time.

**After just 60 days, Tre’s estimated A1C dropped from 8.42% to 7.06%, his average glucose dropped from 195 to 156 mg/dL and his time in range increased by 48%.**

# THE EVERSENSE LONG-TERM CGM SYSTEM: Real patient, real-world outcomes.


▶ **Tre**, age 24, Type 1 diabetes patient, Eversense CGM user since February 2019

▶ **IMPROVED CONTROL ASSOCIATED WITH REDUCED HEALTHCARE UTILIZATION<sup>5</sup>**

**59% less time spent hyperglycemic (above 250 mg/dL)**

## ▶ TRE'S RESULTS:

- > **1.4%** reduction in estimated A1C
- > **156 mg/dL** average glucose
- > **48%** improvement in time in range (70-180 mg/dL)
- > **81%** sensor wear time



To learn more about how Eversense is improving outcomes for patients like Tre and redefining continuous glucose monitoring, visit [eversensed diabetes.com](https://eversensed diabetes.com) today.

1 T1D Exchange; Why Do Some People with T1D Stop Using a Pump and CGM? 2016  
 2 Mean of five publications; McQueen RB, et al Endocr Pract 2014;20:1007-1015. De Bock M, et al. Journal of Diabetes Science and Technology. 2016;10(3):627-632. Raccach D, et al. Diabetes Care 2009;32:2245-2250. Picard S, et al. Diabetes Technol Ther 2016; Mar;18(3):127-35.  
 3 Lind M. JAMA. 2017;317(4):379-387.  
 4 Battelino T. Diabet Med. 2015;32(12):1568-74.  
 5 Bansal, M., et al. Appl Health Econ Health Policy (2018) 16: 675.

The photograph is for illustrative purposes only and depicts a stock photography model. The information presented is Tre's actual data shared with the permission of him and his physician. The patient experience, data, and results presented herein are unique to the individual, and not intended to represent other patient cases. Individual experiences and results may vary.

The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see <https://eversensed diabetes.com/safety-info/>.

